Cidara Therapeutics Analyst Ratings
Cidara Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/06/2023 | 631.71% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 09/22/2023 | 265.85% | Needham | → $3 | Reiterates | Buy → Buy |
| 09/22/2023 | 631.71% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 09/08/2023 | 265.85% | Needham | → $3 | Reiterates | Buy → Buy |
| 09/07/2023 | 631.71% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 08/07/2023 | 631.71% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 08/04/2023 | 265.85% | Needham | → $3 | Reiterates | Buy → Buy |
| 08/01/2023 | 631.71% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 08/01/2023 | 509.76% | Cantor Fitzgerald | → $5 | Reiterates | Overweight → Overweight |
| 06/26/2023 | 631.71% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 05/15/2023 | 631.71% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 05/12/2023 | 265.85% | Needham | → $3 | Reiterates | Buy → Buy |
| 04/18/2023 | 265.85% | Needham | → $3 | Reiterates | → Buy |
| 03/24/2023 | 631.71% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 03/23/2023 | 631.71% | HC Wainwright & Co. | $6.5 → $6 | Maintains | Buy |
| 03/08/2023 | 509.76% | Cantor Fitzgerald | → $5 | Reiterates | → Overweight |
| 03/01/2023 | 692.68% | HC Wainwright & Co. | → $6.5 | Reiterates | → Buy |
| 01/25/2023 | 692.68% | HC Wainwright & Co. | $6 → $6.5 | Maintains | Buy |
| 05/12/2022 | 631.71% | HC Wainwright & Co. | $7.5 → $6 | Maintains | Buy |
| 09/22/2021 | 875.61% | Aegis Capital | $9 → $8 | Maintains | Buy |
| 09/22/2021 | — | WBB Securities | Upgrades | Buy → Strong Buy | |
| 03/04/2021 | 997.56% | Aegis Capital | → $9 | Initiates Coverage On | → Buy |
| 08/26/2020 | 509.76% | Citigroup | $6 → $5 | Maintains | Buy |
| 03/05/2020 | 631.71% | Needham | $10 → $6 | Maintains | Buy |
| 12/04/2019 | 662.2% | WBB Securities | → $6.25 | Upgrades | Speculative Buy → Buy |
| 09/04/2019 | — | Wedbush | Upgrades | Neutral → Outperform | |
| 06/06/2019 | 631.71% | Oppenheimer | → $6 | Initiates Coverage On | → Outperform |
| 05/17/2019 | 143.9% | Wedbush | $7 → $2 | Downgrades | Outperform → Neutral |
| 03/01/2019 | 753.66% | Wedbush | $12 → $7 | Maintains | Outperform |
| 日期 | 上行/下行 | 分析師事務所 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/06/2023 | 631.71% | HC Wainwright & Co. | → 6 美元 | 重申 | 購買 → 購買 |
| 09/22/2023 | 265.85% | 尼德姆 | → 3 美元 | 重申 | 購買 → 購買 |
| 09/22/2023 | 631.71% | HC Wainwright & Co. | → 6 美元 | 重申 | 購買 → 購買 |
| 09/08/2023 | 265.85% | 尼德姆 | → 3 美元 | 重申 | 購買 → 購買 |
| 09/07/2023 | 631.71% | HC Wainwright & Co. | → 6 美元 | 重申 | 購買 → 購買 |
| 08/07/2023 | 631.71% | HC Wainwright & Co. | → 6 美元 | 重申 | → 購買 |
| 08/04/2023 | 265.85% | 尼德姆 | → 3 美元 | 重申 | 購買 → 購買 |
| 08/01/2023 | 631.71% | HC Wainwright & Co. | → 6 美元 | 重申 | → 購買 |
| 08/01/2023 | 509.76% | 坎託·菲茨傑拉德 | → 5 美元 | 重申 | 超重 → 超重 |
| 06/26/2023 | 631.71% | HC Wainwright & Co. | → 6 美元 | 重申 | 購買 → 購買 |
| 05/15/2023 | 631.71% | HC Wainwright & Co. | → 6 美元 | 重申 | 購買 → 購買 |
| 05/12/2023 | 265.85% | 尼德姆 | → 3 美元 | 重申 | 購買 → 購買 |
| 04/18/2023 | 265.85% | 尼德姆 | → 3 美元 | 重申 | → 購買 |
| 2023 年 3 月 24 日 | 631.71% | HC Wainwright & Co. | → 6 美元 | 重申 | → 購買 |
| 03/23/2023 | 631.71% | HC Wainwright & Co. | 6.5 美元 → 6 美元 | 維護 | 購買 |
| 03/08/2023 | 509.76% | 坎託·菲茨傑拉德 | → 5 美元 | 重申 | → 超重 |
| 03/01/2023 | 692.68% | HC Wainwright & Co. | → 6.5 美元 | 重申 | → 購買 |
| 01/25/2023 | 692.68% | HC Wainwright & Co. | 6 美元 → 6.5 美元 | 維護 | 購買 |
| 05/12/2022 | 631.71% | HC Wainwright & Co. | 7.5 美元 → 6 美元 | 維護 | 購買 |
| 2021 年 9 月 22 日 | 875.61% | 宙斯盾資本 | 9 美元 → 8 美元 | 維護 | 購買 |
| 2021 年 9 月 22 日 | — | WBB 證券 | 升級 | 買入 → 強勢買入 | |
| 2021 年 4 月 3 日 | 997.56% | 宙斯盾資本 | → 9 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 08/26/2020 | 509.76% | 花旗集團 | 6 美元 → 5 美元 | 維護 | 購買 |
| 03/05/2020 | 631.71% | 尼德姆 | 10 美元 → 6 美元 | 維護 | 購買 |
| 2019 年 4 月 12 日 | 662.2% | WBB 證券 | → 6.25 美元 | 升級 | 投機性買入 → 買入 |
| 09/04/2019 | — | Wedbush | 升級 | 中性 → 跑贏大盤 | |
| 2019 年 6 月 6 日 | 631.71% | 奧本海默 | → 6 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 05/17/2019 | 143.9% | Wedbush | 7 美元 → 2 美元 | 降級 | 跑贏大盤 → 中立 |
| 03/01/2019 | 753.66% | Wedbush | 12 美元 → 7 美元 | 維護 | 跑贏大盤 |
What is the target price for Cidara Therapeutics (CDTX)?
Cidara Therapeutics（CDTX）的目標價格是多少？
The latest price target for Cidara Therapeutics (NASDAQ: CDTX) was reported by HC Wainwright & Co. on November 6, 2023. The analyst firm set a price target for $6.00 expecting CDTX to rise to within 12 months (a possible 631.71% upside). 18 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年11月6日公佈了Cidara Therapeutics（納斯達克股票代碼：CDTX）的最新目標股價。該分析公司將目標股價設定爲6.00美元，預計CDTX將在12個月內上漲至631.71％（可能上漲631.71％）。去年有18家分析公司公佈了評級。
What is the most recent analyst rating for Cidara Therapeutics (CDTX)?
Cidara Therapeutics（CDTX）的最新分析師評級是多少？
The latest analyst rating for Cidara Therapeutics (NASDAQ: CDTX) was provided by HC Wainwright & Co., and Cidara Therapeutics reiterated their buy rating.
Cidara Therapeutics（納斯達克股票代碼：CDTX）的最新分析師評級由HC Wainwright & Co. 提供，Cidara Therapeutics重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for Cidara Therapeutics (CDTX)?
Cidara Therapeutics（CDTX）的下一個分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cidara Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cidara Therapeutics was filed on November 6, 2023 so you should expect the next rating to be made available sometime around November 6, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Cidara Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Cidara Therapeutics的最後一次評級是在2023年11月6日發佈的，因此您應該預計下一個評級將在2024年11月6日左右公佈。
Is the Analyst Rating Cidara Therapeutics (CDTX) correct?
分析師對Cidara Therapeutics（CDTX）的評級是否正確？
While ratings are subjective and will change, the latest Cidara Therapeutics (CDTX) rating was a reiterated with a price target of $0.00 to $6.00. The current price Cidara Therapeutics (CDTX) is trading at is $0.82, which is within the analyst's predicted range.
儘管評級是主觀的，並將發生變化，但Cidara Therapeutics（CDTX）的最新評級得到了重申，目標股價爲0.00美元至6.00美元。Cidara Therapeutics（CDTX）目前的交易價格爲0.82美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。